Barinthus Biotherapeutics (BRNS) Expected to Announce Quarterly Earnings on Wednesday

Barinthus Biotherapeutics (NASDAQ:BRNS) is projected to announce its earnings results before the market opens on Wednesday, March 19th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter.

Barinthus Biotherapeutics Price Performance

Shares of NASDAQ:BRNS opened at $1.06 on Monday. Barinthus Biotherapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $4.16. The business has a 50-day moving average of $1.02 and a two-hundred day moving average of $1.13. The stock has a market capitalization of $42.64 million, a P/E ratio of -0.71 and a beta of -0.80.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price target on Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, January 13th.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.